The Comptroller General of Indian Medicine (DCGI) has allowed the Serum Institute of India (SII) to re-launch a clinical trial of the coronavirus vaccine in Oxford. The DCGI has approved the Serum Institute for the sec ond phase and the third test of the COMID-19 vaccine. The Serim Institute is developing vaccines for estrogenica in the UK as well as the University of Oxford in India.
The Serum Institute of India (SII) on Tuesday gave permission to Indian Drug Controller General (DCGI) Dr VG Somani to resume clinical trials on Oxford’s Covid-19 vaccine candidates. The serum institute, which manufactures the vaccine in India, has stopped testing the corona vaccine for estrogenica Oxford in Britain.
Serum Institute to start testing for coronavirus vaccine in Ostford as soon as DGCI gets green signal
The DCGI revoked the earlier order prohibiting the selection of any candidate for the second and third stage examinations. However, DCGI has left out other conditions, including extra attention, during the investigation. SGI has been asked by DGCI to submit treatment information as per rules to deal with adverse situation.
Earlier on September 11, the DCGI instructed the Serum Institute of India to suspend clinical trials of a possible Coryd-19 vaccine because the giant drug company AstraZeneca had reported “poor health” in one of the countries involved in the study.
Phase III 3, corona vaccine testing began in India, 1600 people were given this vaccine
In fact the UK drug manufacturer stopped testing the vaccine in September due to a patient’s illness during the test. The vaccine was given to 34 out of 100 people in the Indian Medical School in Pune in the second phase of testing in India from August 2. None of this created any health problems.